These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 32977104)

  • 1. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer: The prognostic impact of baseline neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios.
    Zager Y; Hoffman A; Dreznik Y; Jacoby H; Cordoba M; Horesh N; Nevler A; Gutman M; Berger Y
    Surg Oncol; 2020 Dec; 35():321-327. PubMed ID: 32977104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative platelet-lymphocyte ratio is an independent prognostic marker and superior to carcinoembryonic antigen in colorectal peritoneal carcinomatosis patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Bong TSH; Tan GHC; Chia C; Soo KC; Teo MCC
    Int J Clin Oncol; 2017 Jun; 22(3):511-518. PubMed ID: 28138878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 4. Peritoneal carcinomatosis in colorectal cancer: Defining predictive factors for successful cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A pilot study.
    Mahmoud AM; Ismail YM; Hussien A; Debaky Y; Ahmed IS; Mikhael HSW; Moneer M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):143-150. PubMed ID: 30472198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Construction and evaluation of a nomogram for predicting the prognosis of patients with colorectal cancer with peritoneal carcinomatosis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    An SL; Ji ZH; Li XB; Liu G; Zhang YB; Gao C; Zhang K; Zhang XJ; Yan GJ; Yan LJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):434-441. PubMed ID: 37217351
    [No Abstract]   [Full Text] [Related]  

  • 6. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
    Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
    Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte-to-monocyte ratio predicts survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Pletcher E; Gleeson E; Shaltiel T; Leigh N; Sullivan B; Labow D; Magge D; Golas B; Cohen N; Sarpel U
    Biomark Med; 2021 Aug; 15(12):965-975. PubMed ID: 34289740
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center.
    Huang CQ; Yang XJ; Yu Y; Wu HT; Liu Y; Yonemura Y; Li Y
    PLoS One; 2014; 9(9):e108509. PubMed ID: 25259574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel prognostic score for outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with metachronous peritoneal carcinomatosis.
    Chin KM; Tan GHC; Chia CS; Ong JCA; Teo MCC
    ANZ J Surg; 2020 Oct; 90(10):1958-1964. PubMed ID: 32159299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy on peritoneal carcinomatosis from colorectal cancer].
    An SL; Zhang K; Ji ZH; Li XB; Yu Y; Zhang YB; Liu G; Li B; Yan GJ; Li Y
    Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1298-1303. PubMed ID: 34915640
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.
    Zhou S; Jiang Y; Liang J; Pei W; Zhou Z
    World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
    Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
    World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Outcomes following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin.
    Taqi K; Lee J; Hurton S; Stockley C; Mack L; Rivard J; Temple W; Bouchard-Fortier A
    Curr Oncol; 2024 Jun; 31(7):3657-3668. PubMed ID: 39057141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent.
    Sipok A; Sardi A; Nieroda C; King MC; Sittig M; Gushchin V
    Int J Surg Oncol; 2018; 2018():1920276. PubMed ID: 30643644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases.
    Ljunggren M; Nordenvall C; Palmer G
    Eur J Surg Oncol; 2021 Nov; 47(11):2865-2872. PubMed ID: 34116900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study.
    Solaini L; D'Acapito F; Passardi A; Framarini M; Tauceri F; Di Pietrantonio D; Frassineti GL; Casadei Gardini A; Cucchetti A; Cavaliere D; Ercolani G
    World J Surg Oncol; 2019 Mar; 17(1):58. PubMed ID: 30917826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin.
    Winer J; Zenati M; Ramalingam L; Jones H; Zureikat A; Holtzman M; Lee K; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2014 May; 21(5):1456-62. PubMed ID: 24201745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
    Lee L; Alie-Cusson F; Dubé P; Sideris L
    J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.